CELONTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CELONTIN (CELONTIN).
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
| Metabolism | Metabolized in the liver primarily via hydroxylation and conjugation; metabolites include mesuximide and N-desmethylmethsuximide; CYP450 enzymes involved. |
| Excretion | Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally. |
| Half-life | Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life. |
| Protein binding | Plasma protein binding: approximately 45-70%, primarily to albumin. |
| Volume of Distribution | Apparent volume of distribution: 1.5-2.5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral bioavailability: approximately 80-90% (well absorbed from GI tract). |
| Onset of Action | Oral: clinical effects (seizure control) typically observed within 1-2 hours; steady-state reached after 2-3 weeks. |
| Duration of Action | Duration of antiepileptic effect: 24-48 hours; dosing is typically twice daily to maintain therapeutic levels. |
| Molecular Weight | 141.17 |
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
| Dosage form | CAPSULE |
| Renal impairment | CrCl 50-80 mL/min: 75% of normal dose; CrCl 10-50 mL/min: 50% of normal dose; CrCl <10 mL/min: 25% of normal dose. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Reduce dose by 50%; Class C: Avoid use or reduce dose by 75%. |
| Pediatric use | Children 2-12 years: Initial 10 mg/kg/day orally in divided doses; increase by 10 mg/kg/day every 3-4 days up to 40 mg/kg/day in divided doses. |
| Geriatric use | Start at lower end of dosing range (300 mg daily) due to age-related renal impairment; monitor for sedation and ataxia. |
| 1st trimester | Risk of major congenital malformations, including neural tube defects and congenital heart defects, based on human data from other succinimides. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | Potential for teratogenicity persists; use only if clearly needed. Monitor fetal growth and development. |
| 3rd trimester | Risk of neonatal withdrawal (e.g., irritability, feeding difficulties) and bleeding due to vitamin K deficiency. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for CELONTIN (CELONTIN).
| Placental transfer | Crosses the placenta; human data limited but similar structure to phenytoin suggests significant transfer. Animal studies show maternal-fetal equilibration. |
| Breastfeeding | Excreted into breast milk; low infant doses estimated. Monitor infant for sedation, poor feeding, and unusual bleeding. Consider alternative anticonvulsants with better safety profiles. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to succinimides (ethosuximide, methsuximide)Porphyria
| Precautions | Bone marrow suppression (leukopenia, thrombocytopenia), Systemic lupus erythematosus-like syndrome, Psychiatric effects (aggression, psychosis, depression), Liver dysfunction, Renal impairment, Withdrawal precipitation of seizures |
| Food/Dietary | No specific food interactions reported. Avoid alcohol as it may exacerbate CNS depression. Consistency in timing of meals relative to dosing is advised but not mandatory. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Potential adverse effects but benefit may outweigh risk. |
| Teratogenic Risk | First trimester exposure associated with increased risk of major congenital malformations, particularly neural tube defects, cleft lip/palate, cardiovascular anomalies. Third trimester exposure may cause neonatal withdrawal syndrome, coagulopathy, and respiratory depression. |
| Fetal Monitoring | Monitor maternal serum drug levels, CBC, LFTs, and seizure frequency. Fetal ultrasound for structural anomalies in at-risk pregnancies. Assess neonatal for withdrawal, sedation, and coagulopathy post-delivery. |
| Fertility Effects | No significant adverse effects on fertility reported; however, limited data. Antiepileptic drugs may affect hormonal contraception efficacy; use additional contraceptive measures. |
| CELONTIN (methsuximide) is a succinimide anticonvulsant primarily used for absence seizures. It may exacerbate generalized tonic-clonic seizures. Therapeutic drug monitoring is recommended (target 10-40 mcg/mL). Renal impairment requires dose adjustment. Abrupt withdrawal may precipitate status epilepticus. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly. · May cause dizziness or drowsiness; avoid driving until effects known. · Report rash, fever, or unusual bleeding/bruising immediately. · Use effective contraception if childbearing potential. · Regular blood tests are necessary to monitor drug levels and liver function. |